VISEN Pharmaceuticals operates as a biopharmaceutical company. The company is headquartered in Suzhou, Jiangsu and currently employs 54 full-time employees. The company went IPO on 2025-03-21. The firm's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The firm is in the late stage of research and development, and its products are close to commercialization.
02561.HK stock price ended at $33.56 on Jueves, after rising 0.78%
On the latest trading day Feb 12, 2026, the stock price of 02561.HK rose by 0.78%, climbing from $33.84 to $33.56. Throughout the session, the stock experienced a volatility of 3.74%, with prices fluctuating between a daily low of $32.62 and a high of $33.84. Alongside this price increase, trading volume also rose by 31.4K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 2.8K shares were traded, amounting to a market value of approximately $3.8B.
Señales Técnicas de 02561.HK
Resumen de Señales Técnicas
Señales de compra 3
Señales Neutras 1
Señales de venta 3
Strong Sell
Sell
Neutral
Buy
Strong Buy
02561.HK actualmente presenta 3 señales de compra y 3 señales de venta. La acción ha estado en una tendencia alcista desde 12:00 AM, con un cambio total en el precio de 0.78% durante este período. En general, los indicadores técnicos apuntan a una perspectiva Neutral para el mediano plazo.
Señales alcistas/bajistas para 02561.HK
Analizamos indicadores clave como medias móviles, RSI, MACD y volumen de negociación para generar señales alcistas y bajistas para 02561.HK. Estas perspectivas te ayudan a tomar decisiones de inversión más informadas.